Contralateral Prophylactic Mastectomy Provides No Survival Benefit in Young Women with Estrogen Receptor-Negative Breast Cancer

Annals of Surgical Oncology

Volumn 21, Issue 10, 2014, Pages 3231-3239

  Pesce, Catherine ^a   Liederbach, Erik ^a   Wang, Chihsiung ^a   Lapin, Brittany ^a   Winchester, David J ^a   Yao, Katharine ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADOLESCENT; ADULT; BREAST NEOPLASMS; CANCER GRADING; CANCER REGISTRY; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HUMAN; MASTECTOMY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SELECTION BIAS; SURVIVAL RATE; TUMOR INVASION; YOUNG ADULT;

ADOLESCENT; ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; SEER PROGRAM; SELECTION BIAS; SURVIVAL RATE; YOUNG ADULT;

EID: 84930983974     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3956-3     Document Type: Article

References (27)

1. Arrington AK, Jarosek SL, Virnig BA, et al. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16(10):2697–704.
2. Yao K, Stewart AK, Winchester DJ, et al. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998–2007. Ann Surg Oncol. 2010;17(10):2554–62.
3. Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203–9.
4. Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27(9):1362–7.
5. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158–64.
6. Lostumbo L, Carbine N, Wallace J, et al. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Review. 2004;(4):CD002748.
7. Yao K, Winchester DJ, Czechura T, et al. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002. Breast Cancer Res Treat. 2013;142(3):465–76.
8. Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23(19):4275–86.
9. Peralta EA, Ellenhorn JD, Wagman LD, et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180(6):439–45.
10. Boughey J, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17(10):2702–09.
11. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102(6):401–9.
12. Brewster A, Bedrosian I, Parker PA, et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012;118(22):5637–43.
13. Winchester DP, Stewart AK, Bura C, et al. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol. 2004;85:1–3.
14. Bilimoria KY, Stewart AK, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.
15. Dayo RA, Cherkin DC, Ciol MA, et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;44:613–9.
16. US Census Bureau. USC 2000. http://www.census.gov/main/www/cen2000.html. Accessed 13 Apr 2014.
17. Edge S, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
18. Fritz A, Percy C, Jack A. ICD-O: International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.
19. Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, et al. Declining incidence of contralateral breast cancer in the United States from 1975–2006. J Clin Oncol. 2011;29(12):1564–9.
20. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56(4):1038–45.
21. Kurian AW, McClur LA, John EM, et al. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009;101(15):1058–65.
22. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998;352(9132):930–42.
23. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328–35.
24. Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226. doi: 10.1136/bmj.g226.
25. Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet. 2008;124(1):31–42.
26. Reiner AS, John EM, Brooks JD, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013;31(4):433–439.
27. Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 2013;159(6):373–81.